Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the psoriasis drug market will reach $3.9 billion in 2011. A major factor in growth of the market, especially in the first half of the 2001-2011 forecast period, will be the entry into the market of biologic agents, according to a new Pharmacor report entitled Psoriasis.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"The launch of several biologic agents for psoriasis during our forecast period, 2001 through 2011, will drive up the psoriasis market significantly, principally because of the anticipated high cost of these therapies relative to more traditional therapies," said Sylvia Marecki, Ph.D., analyst at Decision Resources. "However, the biologic agents are indicated for moderate to severe psoriasis. This scope means that the agents will be used in less than 30% of psoriasis cases; the majority of psoriasis patients are diagnosed with mild disease."

Disease Background-Psoriasis

Psoriasis is an inflammatory skin disorder that affects an estimated 1-2% of the population--more than 10 million people--in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). The clinical presentation of psoriasis varies greatly among affected patients and may even vary markedly in an individual patient during the course of the disease; it may be as innocuous as a single pit in a fingernail or as serious as generalized, disfiguring skin lesions and disabling psoriatic arthritis. Advances in the understanding of psoriasis have enabled the development of several new therapeutic agents.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Psoriasis is an Immune and Inflammatory Disorders report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X32468127

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Drugs Intended for The Treatment of Epilepsy and Schizophrenia Are Often Used for Other Diseases

View Now